Data as of Oct 24
| +0.56 / +1.58%|
The 8 analysts offering 12-month price forecasts for Haemonetics Corp have a median target of 37.50, with a high estimate of 50.00 and a low estimate of 30.00. The median estimate represents a +4.17% increase from the last price of 36.00.
The current consensus among 12 polled investment analysts is to Hold stock in Haemonetics Corp. This rating has held steady since October, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.